United States Anti-Obesity Prescription Drugs Market Report 2017

December 2017 | 97 pages | ID: U1B3418BBF5EN
QYResearch

Abstracts

In this report, the United States Anti-Obesity Prescription Drugs market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022.

Geographically, this report splits the United States market into seven regions:

• The West
• Southwest
• The Middle Atlantic
• New England
• The South
• The Midwest
• with sales (volume), revenue (value), market share and growth rate of Anti-Obesity Prescription Drugs in these regions, from 2012 to 2022 (forecast).

United States Anti-Obesity Prescription Drugs market competition by top manufacturers/players, with Anti-Obesity Prescription Drugs sales volume, price, revenue (Million USD) and market share for each manufacturer/player; the top players including

• VIVUS
• Orexigen Therapeutics
• Novo Nordisk
• F Hoffmann La Roche
• Arena Pharmaceuticals

On the basis of product, this report displays the production, revenue, price, market share and growth rate of each type, primarily split into

• Bupropion and Naltrexone
• Orlistat
• Lorcaserin
• Phentermine and Topiramate
• Liraglutide

On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume, market share and growth rate for each application, including

• Hospitals Pharmacies
• Retail Pharmacies
• E-commerce

If you have any special requirements, please let us know and we will offer you the report as you want.

Contents

United States Anti-Obesity Prescription Drugs Market Report 2017

1 ANTI-OBESITY PRESCRIPTION DRUGS OVERVIEW

1.1 Product Overview and Scope of Anti-Obesity Prescription Drugs
1.2 Classification of Anti-Obesity Prescription Drugs by Product Category
  1.2.1 United States Anti-Obesity Prescription Drugs Market Size (Sales Volume) Comparison by Type (2012-2022)
  1.2.2 United States Anti-Obesity Prescription Drugs Market Size (Sales Volume) Market Share by Type (Product Category) in 2016
  1.2.3 Bupropion and Naltrexone
  1.2.4 Orlistat
  1.2.5 Lorcaserin
  1.2.6 Phentermine and Topiramate
  1.2.7 Liraglutide
1.3 United States Anti-Obesity Prescription Drugs Market by Application/End Users
  1.3.1 United States Anti-Obesity Prescription Drugs Market Size (Consumption) and Market Share Comparison by Application (2012-2022)
  1.3.2 Hospitals Pharmacies
  1.3.3 Retail Pharmacies
  1.3.4 E-commerce
1.4 United States Anti-Obesity Prescription Drugs Market by Region
  1.4.1 United States Anti-Obesity Prescription Drugs Market Size (Value) Comparison by Region (2012-2022)
  1.4.2 The West Anti-Obesity Prescription Drugs Status and Prospect (2012-2022)
  1.4.3 Southwest Anti-Obesity Prescription Drugs Status and Prospect (2012-2022)
  1.4.4 The Middle Atlantic Anti-Obesity Prescription Drugs Status and Prospect (2012-2022)
  1.4.5 New England Anti-Obesity Prescription Drugs Status and Prospect (2012-2022)
  1.4.6 The South Anti-Obesity Prescription Drugs Status and Prospect (2012-2022)
  1.4.7 The Midwest Anti-Obesity Prescription Drugs Status and Prospect (2012-2022)
1.5 United States Market Size (Value and Volume) of Anti-Obesity Prescription Drugs (2012-2022)
  1.5.1 United States Anti-Obesity Prescription Drugs Sales and Growth Rate (2012-2022)
  1.5.2 United States Anti-Obesity Prescription Drugs Revenue and Growth Rate (2012-2022)

2 UNITED STATES ANTI-OBESITY PRESCRIPTION DRUGS MARKET COMPETITION BY PLAYERS/SUPPLIERS

2.1 United States Anti-Obesity Prescription Drugs Sales and Market Share of Key Players/Suppliers (2012-2017)
2.2 United States Anti-Obesity Prescription Drugs Revenue and Share by Players/Suppliers (2012-2017)
2.3 United States Anti-Obesity Prescription Drugs Average Price by Players/Suppliers (2012-2017)
2.4 United States Anti-Obesity Prescription Drugs Market Competitive Situation and Trends
  2.4.1 United States Anti-Obesity Prescription Drugs Market Concentration Rate
  2.4.2 United States Anti-Obesity Prescription Drugs Market Share of Top 3 and Top 5 Players/Suppliers
  2.4.3 Mergers & Acquisitions, Expansion in United States Market
2.5 United States Players/Suppliers Anti-Obesity Prescription Drugs Manufacturing Base Distribution, Sales Area, Product Type

3 UNITED STATES ANTI-OBESITY PRESCRIPTION DRUGS SALES (VOLUME) AND REVENUE (VALUE) BY REGION (2012-2017)

3.1 United States Anti-Obesity Prescription Drugs Sales and Market Share by Region (2012-2017)
3.2 United States Anti-Obesity Prescription Drugs Revenue and Market Share by Region (2012-2017)
3.3 United States Anti-Obesity Prescription Drugs Price by Region (2012-2017)

4 UNITED STATES ANTI-OBESITY PRESCRIPTION DRUGS SALES (VOLUME) AND REVENUE (VALUE) BY TYPE (PRODUCT CATEGORY) (2012-2017)

4.1 United States Anti-Obesity Prescription Drugs Sales and Market Share by Type (Product Category) (2012-2017)
4.2 United States Anti-Obesity Prescription Drugs Revenue and Market Share by Type (2012-2017)
4.3 United States Anti-Obesity Prescription Drugs Price by Type (2012-2017)
4.4 United States Anti-Obesity Prescription Drugs Sales Growth Rate by Type (2012-2017)

5 UNITED STATES ANTI-OBESITY PRESCRIPTION DRUGS SALES (VOLUME) BY APPLICATION (2012-2017)

5.1 United States Anti-Obesity Prescription Drugs Sales and Market Share by Application (2012-2017)
5.2 United States Anti-Obesity Prescription Drugs Sales Growth Rate by Application (2012-2017)
5.3 Market Drivers and Opportunities

6 UNITED STATES ANTI-OBESITY PRESCRIPTION DRUGS PLAYERS/SUPPLIERS PROFILES AND SALES DATA

6.1 VIVUS
  6.1.1 Company Basic Information, Manufacturing Base and Competitors
  6.1.2 Anti-Obesity Prescription Drugs Product Category, Application and Specification
    6.1.2.1 Product A
    6.1.2.2 Product B
  6.1.3 VIVUS Anti-Obesity Prescription Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
  6.1.4 Main Business/Business Overview
6.2 Orexigen Therapeutics
  6.2.2 Anti-Obesity Prescription Drugs Product Category, Application and Specification
    6.2.2.1 Product A
    6.2.2.2 Product B
  6.2.3 Orexigen Therapeutics Anti-Obesity Prescription Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
  6.2.4 Main Business/Business Overview
6.3 Novo Nordisk
  6.3.2 Anti-Obesity Prescription Drugs Product Category, Application and Specification
    6.3.2.1 Product A
    6.3.2.2 Product B
  6.3.3 Novo Nordisk Anti-Obesity Prescription Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
  6.3.4 Main Business/Business Overview
6.4 F Hoffmann La Roche
  6.4.2 Anti-Obesity Prescription Drugs Product Category, Application and Specification
    6.4.2.1 Product A
    6.4.2.2 Product B
  6.4.3 F Hoffmann La Roche Anti-Obesity Prescription Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
  6.4.4 Main Business/Business Overview
6.5 Arena Pharmaceuticals
  6.5.2 Anti-Obesity Prescription Drugs Product Category, Application and Specification
    6.5.2.1 Product A
    6.5.2.2 Product B
  6.5.3 Arena Pharmaceuticals Anti-Obesity Prescription Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
  6.5.4 Main Business/Business Overview

7 ANTI-OBESITY PRESCRIPTION DRUGS MANUFACTURING COST ANALYSIS

7.1 Anti-Obesity Prescription Drugs Key Raw Materials Analysis
  7.1.1 Key Raw Materials
  7.1.2 Price Trend of Key Raw Materials
  7.1.3 Key Suppliers of Raw Materials
  7.1.4 Market Concentration Rate of Raw Materials
7.2 Proportion of Manufacturing Cost Structure
  7.2.1 Raw Materials
  7.2.2 Labor Cost
  7.2.3 Manufacturing Expenses
7.3 Manufacturing Process Analysis of Anti-Obesity Prescription Drugs

8 INDUSTRIAL CHAIN, SOURCING STRATEGY AND DOWNSTREAM BUYERS

8.1 Anti-Obesity Prescription Drugs Industrial Chain Analysis
8.2 Upstream Raw Materials Sourcing
8.3 Raw Materials Sources of Anti-Obesity Prescription Drugs Major Manufacturers in 2016
8.4 Downstream Buyers

9 MARKETING STRATEGY ANALYSIS, DISTRIBUTORS/TRADERS

9.1 Marketing Channel
  9.1.1 Direct Marketing
  9.1.2 Indirect Marketing
  9.1.3 Marketing Channel Development Trend
9.2 Market Positioning
  9.2.1 Pricing Strategy
  9.2.2 Brand Strategy
  9.2.3 Target Client
9.3 Distributors/Traders List

10 MARKET EFFECT FACTORS ANALYSIS

10.1 Technology Progress/Risk
  10.1.1 Substitutes Threat
  10.1.2 Technology Progress in Related Industry
10.2 Consumer Needs/Customer Preference Change
10.3 Economic/Political Environmental Change

11 UNITED STATES ANTI-OBESITY PRESCRIPTION DRUGS MARKET SIZE (VALUE AND VOLUME) FORECAST (2017-2022)

11.1 United States Anti-Obesity Prescription Drugs Sales Volume, Revenue Forecast (2017-2022)
11.2 United States Anti-Obesity Prescription Drugs Sales Volume Forecast by Type (2017-2022)
11.3 United States Anti-Obesity Prescription Drugs Sales Volume Forecast by Application (2017-2022)
11.4 United States Anti-Obesity Prescription Drugs Sales Volume Forecast by Region (2017-2022)

12 RESEARCH FINDINGS AND CONCLUSION

13 APPENDIX

13.1 Methodology/Research Approach
  13.1.1 Research Programs/Design
  13.1.2 Market Size Estimation
  13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
  13.2.1 Secondary Sources
  13.2.2 Primary Sources
13.3 Disclaimer


The report requires updating with new data and is sent in 2-3 business days after order is placed.

List Of Tables

LIST OF TABLES AND FIGURES

Figure Product Picture of Anti-Obesity Prescription Drugs
Figure United States Anti-Obesity Prescription Drugs Market Size (K Units) by Type (2012-2022)
Figure United States Anti-Obesity Prescription Drugs Sales Volume Market Share by Type (Product Category) in 2016
Figure Bupropion and Naltrexone Product Picture
Figure Orlistat Product Picture
Figure Lorcaserin Product Picture
Figure Phentermine and Topiramate Product Picture
Figure Liraglutide Product Picture
Figure United States Anti-Obesity Prescription Drugs Market Size (K Units) by Application (2012-2022)
Figure United States Sales Market Share of Anti-Obesity Prescription Drugs by Application in 2016
Figure Hospitals Pharmacies Examples
Table Key Downstream Customer in Hospitals Pharmacies
Figure Retail Pharmacies Examples
Table Key Downstream Customer in Retail Pharmacies
Figure E-commerce Examples
Table Key Downstream Customer in E-commerce
Figure United States Anti-Obesity Prescription Drugs Market Size (Million USD) by Region (2012-2022)
Figure The West Anti-Obesity Prescription Drugs Revenue (Million USD) and Growth Rate (2012-2022)
Figure Southwest Anti-Obesity Prescription Drugs Revenue (Million USD) and Growth Rate (2012-2022)
Figure The Middle Atlantic Anti-Obesity Prescription Drugs Revenue (Million USD) and Growth Rate (2012-2022)
Figure New England Anti-Obesity Prescription Drugs Revenue (Million USD) and Growth Rate (2012-2022)
Figure The South of US Anti-Obesity Prescription Drugs Revenue (Million USD) and Growth Rate (2012-2022)
Figure The Midwest Anti-Obesity Prescription Drugs Revenue (Million USD) and Growth Rate (2012-2022)
Figure United States Anti-Obesity Prescription Drugs Sales (K Units) and Growth Rate (2012-2022)
Figure United States Anti-Obesity Prescription Drugs Revenue (Million USD) and Growth Rate (2012-2022)
Figure United States Anti-Obesity Prescription Drugs Market Major Players Product Sales Volume (K Units) (2012-2017)
Table United States Anti-Obesity Prescription Drugs Sales (K Units) of Key Players/Suppliers (2012-2017)
Table United States Anti-Obesity Prescription Drugs Sales Share by Players/Suppliers (2012-2017)
Figure 2016 United States Anti-Obesity Prescription Drugs Sales Share by Players/Suppliers
Figure 2017 United States Anti-Obesity Prescription Drugs Sales Share by Players/Suppliers
Figure United States Anti-Obesity Prescription Drugs Market Major Players Product Revenue (Million USD) (2012-2017)
Table United States Anti-Obesity Prescription Drugs Revenue (Million USD) by Players/Suppliers (2012-2017)
Table United States Anti-Obesity Prescription Drugs Revenue Share by Players/Suppliers (2012-2017)
Figure 2016 United States Anti-Obesity Prescription Drugs Revenue Share by Players/Suppliers
Figure 2017 United States Anti-Obesity Prescription Drugs Revenue Share by Players/Suppliers
Table United States Market Anti-Obesity Prescription Drugs Average Price (USD/Unit) of Key Players/Suppliers (2012-2017)
Figure United States Market Anti-Obesity Prescription Drugs Average Price (USD/Unit) of Key Players/Suppliers in 2016
Figure United States Anti-Obesity Prescription Drugs Market Share of Top 3 Players/Suppliers
Figure United States Anti-Obesity Prescription Drugs Market Share of Top 5 Players/Suppliers
Table United States Players/Suppliers Anti-Obesity Prescription Drugs Manufacturing Base Distribution and Sales Area
Table United States Players/Suppliers Anti-Obesity Prescription Drugs Product Category
Table United States Anti-Obesity Prescription Drugs Sales (K Units) by Region (2012-2017)
Table United States Anti-Obesity Prescription Drugs Sales Share by Region (2012-2017)
Figure United States Anti-Obesity Prescription Drugs Sales Share by Region (2012-2017)
Figure United States Anti-Obesity Prescription Drugs Sales Market Share by Region in 2016
Table United States Anti-Obesity Prescription Drugs Revenue (Million USD) and Market Share by Region (2012-2017)
Table United States Anti-Obesity Prescription Drugs Revenue Share by Region (2012-2017)
Figure United States Anti-Obesity Prescription Drugs Revenue Market Share by Region (2012-2017)
Figure United States Anti-Obesity Prescription Drugs Revenue Market Share by Region in 2016
Table United States Anti-Obesity Prescription Drugs Price (USD/Unit) by Region (2012-2017)
Table United States Anti-Obesity Prescription Drugs Sales (K Units) by Type (2012-2017)
Table United States Anti-Obesity Prescription Drugs Sales Share by Type (2012-2017)
Figure United States Anti-Obesity Prescription Drugs Sales Share by Type (2012-2017)
Figure United States Anti-Obesity Prescription Drugs Sales Market Share by Type in 2016
Table United States Anti-Obesity Prescription Drugs Revenue (Million USD) and Market Share by Type (2012-2017)
Table United States Anti-Obesity Prescription Drugs Revenue Share by Type (2012-2017)
Figure Revenue Market Share of Anti-Obesity Prescription Drugs by Type (2012-2017)
Figure Revenue Market Share of Anti-Obesity Prescription Drugs by Type in 2016
Table United States Anti-Obesity Prescription Drugs Price (USD/Unit) by Types (2012-2017)
Figure United States Anti-Obesity Prescription Drugs Sales Growth Rate by Type (2012-2017)
Table United States Anti-Obesity Prescription Drugs Sales (K Units) by Application (2012-2017)
Table United States Anti-Obesity Prescription Drugs Sales Market Share by Application (2012-2017)
Figure United States Anti-Obesity Prescription Drugs Sales Market Share by Application (2012-2017)
Figure United States Anti-Obesity Prescription Drugs Sales Market Share by Application in 2016
Table United States Anti-Obesity Prescription Drugs Sales Growth Rate by Application (2012-2017)
Figure United States Anti-Obesity Prescription Drugs Sales Growth Rate by Application (2012-2017)
Table VIVUS Basic Information List
Table VIVUS Anti-Obesity Prescription Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)
Figure VIVUS Anti-Obesity Prescription Drugs Sales Growth Rate (2012-2017)
Figure VIVUS Anti-Obesity Prescription Drugs Sales Market Share in United States (2012-2017)
Figure VIVUS Anti-Obesity Prescription Drugs Revenue Market Share in United States (2012-2017)
Table Orexigen Therapeutics Basic Information List
Table Orexigen Therapeutics Anti-Obesity Prescription Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)
Figure Orexigen Therapeutics Anti-Obesity Prescription Drugs Sales Growth Rate (2012-2017)
Figure Orexigen Therapeutics Anti-Obesity Prescription Drugs Sales Market Share in United States (2012-2017)
Figure Orexigen Therapeutics Anti-Obesity Prescription Drugs Revenue Market Share in United States (2012-2017)
Table Novo Nordisk Basic Information List
Table Novo Nordisk Anti-Obesity Prescription Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)
Figure Novo Nordisk Anti-Obesity Prescription Drugs Sales Growth Rate (2012-2017)
Figure Novo Nordisk Anti-Obesity Prescription Drugs Sales Market Share in United States (2012-2017)
Figure Novo Nordisk Anti-Obesity Prescription Drugs Revenue Market Share in United States (2012-2017)
Table F Hoffmann La Roche Basic Information List
Table F Hoffmann La Roche Anti-Obesity Prescription Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)
Figure F Hoffmann La Roche Anti-Obesity Prescription Drugs Sales Growth Rate (2012-2017)
Figure F Hoffmann La Roche Anti-Obesity Prescription Drugs Sales Market Share in United States (2012-2017)
Figure F Hoffmann La Roche Anti-Obesity Prescription Drugs Revenue Market Share in United States (2012-2017)
Table Arena Pharmaceuticals Basic Information List
Table Arena Pharmaceuticals Anti-Obesity Prescription Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)
Figure Arena Pharmaceuticals Anti-Obesity Prescription Drugs Sales Growth Rate (2012-2017)
Figure Arena Pharmaceuticals Anti-Obesity Prescription Drugs Sales Market Share in United States (2012-2017)
Figure Arena Pharmaceuticals Anti-Obesity Prescription Drugs Revenue Market Share in United States (2012-2017)
Table Production Base and Market Concentration Rate of Raw Material
Figure Price Trend of Key Raw Materials
Table Key Suppliers of Raw Materials
Figure Manufacturing Cost Structure of Anti-Obesity Prescription Drugs
Figure Manufacturing Process Analysis of Anti-Obesity Prescription Drugs
Figure Anti-Obesity Prescription Drugs Industrial Chain Analysis
Table Raw Materials Sources of Anti-Obesity Prescription Drugs Major Players/Suppliers in 2016
Table Major Buyers of Anti-Obesity Prescription Drugs
Table Distributors/Traders List
Figure United States Anti-Obesity Prescription Drugs Sales Volume (K Units) and Growth Rate Forecast (2017-2022)
Figure United States Anti-Obesity Prescription Drugs Revenue (Million USD) and Growth Rate Forecast (2017-2022)
Figure United States Anti-Obesity Prescription Drugs Price (USD/Unit) Trend Forecast (2017-2022)
Table United States Anti-Obesity Prescription Drugs Sales Volume (K Units) Forecast by Type (2017-2022)
Figure United States Anti-Obesity Prescription Drugs Sales Volume (K Units) Forecast by Type (2017-2022)
Figure United States Anti-Obesity Prescription Drugs Sales Volume (K Units) Forecast by Type in 2022
Table United States Anti-Obesity Prescription Drugs Sales Volume (K Units) Forecast by Application (2017-2022)
Figure United States Anti-Obesity Prescription Drugs Sales Volume (K Units) Forecast by Application (2017-2022)
Figure United States Anti-Obesity Prescription Drugs Sales Volume (K Units) Forecast by Application in 2022
Table United States Anti-Obesity Prescription Drugs Sales Volume (K Units) Forecast by Region (2017-2022)
Table United States Anti-Obesity Prescription Drugs Sales Volume Share Forecast by Region (2017-2022)
Figure United States Anti-Obesity Prescription Drugs Sales Volume Share Forecast by Region (2017-2022)
Figure United States Anti-Obesity Prescription Drugs Sales Volume Share Forecast by Region in 2022
Table Research Programs/Design for This Report
Figure Bottom-up and Top-down Approaches for This Report
Figure Data Triangulation
Table Key Data Information from Secondary Sources
Table Key Data Information from Primary Sources